Emcure Pharmaceuticals has reported a strong performance in the second quarter of FY27, with consolidated revenue rising 24.3% year-on-year to Rs 28,205 million and net profit climbing 29.3% to Rs 3,251 million, driven by robust growth in its international business and improved operating profitability.

 

The pharmaceutical major's EBITDA surged 30.9% to Rs 5,748 million during the quarter, while its EBITDA margin expanded 103 basis points year-on-year to 20.4%. The PAT margin also improved by 45 basis points to 11.5%.

 

International operations emerged as the biggest growth driver, posting a 34.5% increase in revenue to Rs 16,652 million. The domestic business recorded 12% growth, taking revenue to Rs 11,553 million.

 

Commenting on the performance, Satish Mehta, Chairman, Managing Director and CEO of Emcure Pharmaceuticals Ltd., said, "Q2 was another strong quarter for Emcure, with broad-based growth in revenue, profitability and earnings.

 

"Revenue grew 24% year-on-year to INR 28,205 Mn, with India growing 12% and International 34.5%. EBITDA grew 31% to INR 5,748 Mn, with margin at 20.4%, an expansion of about 100 basis points, driven by productivity gains and operating leverage. PAT grew 29% to INR 3,251 Mn. We expect business momentum to sustain into H2FY27.”

 

For the first half of FY27, consolidated revenue increased 23.6% to Rs 54,009 million. Domestic revenue grew 11.1% to Rs 22,506 million, while international revenue surged 34.5% to Rs 31,503 million.

 

The domestic business accounted for 41% of consolidated revenue in Q2, with sales reaching Rs 11,553 million. Growth was led by the Women's Health franchise, Cardio-Metabolics and the CNS portfolio, alongside improved traction in Poviztra.

 

Zuventus also reported a sequential improvement in performance, while consumer health brands Bitter Drops and Galact gained traction.

 

Emcure invested Rs 1,110 million in research and development during the quarter, equivalent to around 4% of revenue. Its net debt stood at Rs 13,171 million as of September 30, 2026.

 

The company said it expects business momentum to sustain in the second half of FY27, following a quarter marked by double-digit revenue growth and stronger profitability.